EpCAM expression in upper digestive, respiratory tract and (neuro)endocrine cancers
| Tumour type (no. of samples) | No EpCAM overexpression* | EpCAM overexpression* | ||||||
| No expression (TIS 0) | Weak expression (TIS 1–4) | Moderate expression (TIS 6, 8) | Intense expression (TIS 9, 12) | |||||
| n | % | n | % | n | % | n | % | |
| Oral cavity cancer, SCC (126) | 51 | 40 | 48 | 38 | 11 | 9 | 16 | 13 |
| Non-small-cell lung cancer (146) | 11 | 7 | 28 | 19 | 36 | 25 | 71 | 49 |
| Small cell lung cancer and other PDNET (60) | 12 | 20 | 3 | 5 | 18 | 30 | 27 | 45 |
| WDNET (53) | 2 | 4 | 4 | 8 | 2 | 4 | 45 | 84 |
| Differentiated thyroid cancer (88) | 2 | 3 | 9 | 10 | 25 | 28 | 52 | 59 |
EpCAM expression was determined by immunohistochemistry.
↵* EpCAM overexpression defined by Gastl et al3.
EpCAM, epithelial cell adhesion molecule; PDNET, poorly differentiated neuroendocrine tumour; SCC, squamous cell cancer; TIS, total immunostaining score; WDNET, well-differentiated neuroendocrine tumour.